Literature DB >> 16194725

School performance in early and continuously treated phenylketonuria.

Rosa Gassió1, Eugenia Fusté, Anna López-Sala, Rafael Artuch, María Antonia Vilaseca, Jaume Campistol.   

Abstract

This study investigated the relationship between school performance, cognitive functions, and dietary control in a group of 26 early and continuously treated phenylketonuric patients, in comparison with 21 sex- and age-matched control subjects. The cognitive functions study included intelligence measurement, visual and auditory memory and auditory verbal learning abilities, attention, visuospatial, fine motor, language, and executive functions. Participants were asked about school performance. The indexes of dietary control for the first 6 years of life and for the 6 months before the study were calculated. The intelligence score was significantly lower in phenylketonuric patients (P < 0.0001). The percentage of patients with attention problems (P = 0.02), fine motor (P = 0.001) and executive dysfunctions (P = 0.013) was significantly higher than that for control subjects. Patients had more school problems than controls (P = 0.028). Intelligence score was also significantly lower in these patients (P = 0.046). The index of dietary control for the last 6 months was significantly higher than the index for the first 6 years of life, but only in the patients with school problems (P = 0.033). In conclusion, phenylketonuric patients presented more school problems than control subjects, probably related to the disturbed cognitive functions observed. The index of dietary control for the last 6 months yielded a close relationship with school performance.

Entities:  

Mesh:

Year:  2005        PMID: 16194725     DOI: 10.1016/j.pediatrneurol.2005.05.003

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  12 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents.

Authors:  Eva Thimm; Lisa Elena Schmidt; Katrin Heldt; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

3.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

4.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

5.  Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.

Authors:  Nicola Longo; Cary O Harding; Barbara K Burton; Dorothy K Grange; Jerry Vockley; Melissa Wasserstein; Gregory M Rice; Alejandro Dorenbaum; Jutta K Neuenburg; Donald G Musson; Zhonghua Gu; Saba Sile
Journal:  Lancet       Date:  2014-04-14       Impact factor: 79.321

Review 6.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 7.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

Review 8.  Caring for children with phenylketonuria.

Authors:  Linda Casey
Journal:  Can Fam Physician       Date:  2013-08       Impact factor: 3.275

9.  Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy.

Authors:  Nicola Longo; Komudi Siriwardena; Annette Feigenbaum; David Dimmock; Barbara K Burton; Sylvia Stockler; Susan Waisbren; William Lang; Elaina Jurecki; Charlie Zhang; Suyash Prasad
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

10.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.